DEFA14A: Zevra Therapeutics Urges Stockholders to Re-elect Board Members Amidst Proxy Fight

Zevra Therapeutics files its definitive proxy statement, urging stockholders to vote for its director nominees to defend board independence against a 2.8% stockholder seeking to gain majority control.

Summary

• Zevra Therapeutics has filed its definitive proxy statement for the 2025 Annual Meeting of Stockholders, scheduled for May 29, 2025.
• The Board of Directors recommends stockholders vote for the re-election of Wendy L. Dixon, Ph.D., and Tamara A. Favorito.
• The company highlights a 54.8% total stockholder return since October 2023 under the current board and management.
• An individual stockholder, Daniel J. Mangless, who owns 2.8% of the company, is seeking to replace two directors with his own nominees.
• The company argues that Mr. Mangless' nominees lack the necessary expertise and have a history of destroying stockholder value.
• Zevra emphasizes its strategic plan and recent successes, including the launch of two rare disease therapies and the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million.
• The company is focused on expanding the adoption of MIPLYFFA and OLPRUVA, securing regulatory approval for MIPLYFFA in the EU, and accelerating enrollment in the Phase 3 DiSCOVER trial for celiprolol.
• The board believes that electing Mr. Mangless' nominees would disrupt the company's progress and jeopardize its ability to deliver long-term value.

Sentiment

Score: 7

Explanation: The document presents a confident outlook on the company's performance and future prospects, but it also acknowledges the challenges posed by the proxy fight. The positive tone is tempered by the potential risks associated with the dissident stockholder's actions.

Positives

• The company has delivered a 54.8% total stockholder return since October 2023.
• Zevra has launched two rare disease therapies, MIPLYFFA and OLPRUVA.
• The company sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million, enhancing financial flexibility.
• Zevra is on track to file a marketing authorization application (MAA) for MIPLYFFA in the EU in the second half of 2025.
• The company has a clear five-year strategic plan focused on commercial excellence, pipeline and innovation, talent and culture, and corporate foundation.
• Zevra restructured its debt and secured a new credit facility in April 2024.

Negatives

• Daniel J. Mangless, a 2.8% stockholder, is attempting to gain additional board seats, potentially disrupting the company's progress.
• Mr. Mangless' nominees are criticized for lacking relevant industry experience and having a history of destroying stockholder value.
• The company's former CEO, Dr. Travis Mickle, oversaw a 97.4% drop in the stock price during his tenure.
• One of Mr. Mangless' nominees, Arthur Regan, was a director at US Wats, where the stock price fell 63.9%.

Risks

• The proxy contest initiated by Daniel J. Mangless could distract from the company's strategic goals.
• Electing Mr. Mangless' nominees could lead to disruption and potential destruction of company value.
• The company faces the risk of undue influence from a single stockholder.
• There is a risk that the former CEO, if elected as a director, could seek to micromanage the executive team or pursue a return to his previous role.

Future Outlook

Zevra intends to maintain focus on accelerating its momentum, expanding the adoption of MIPLYFFA and OLPRUVA, securing regulatory approval of MIPLYFFA in the EU, and accelerating enrollment in the Phase 3 DiSCOVER trial for celiprolol.

Management Comments

• The Zevra Board of Directors and management team have taken decisive action over the past two years, transforming the Company and driving significant stockholder value creation.
• We are making significant progress as we successfully drive towards our clear priorities and achieve our vision of positioning Zevra as a leading global rare disease company.
• Your Board and Management Team have a clear path forward to continue delivering value for all Zevra stockholders as we advance the Companys transformation into a leading rare disease company.

Industry Context

The announcement highlights the increasing focus on rare disease therapies and the competitive landscape within the biotechnology sector. The proxy fight reflects a broader trend of activist investors seeking to influence corporate strategy and governance.

Comparison to Industry Standards

• The document mentions that Zevra's total stockholder returns have exceeded the comparable biotech sector and the Russell 2000.
• The document compares the performance of Zevra's stock price under different leadership, highlighting the current management's success compared to the previous CEO's tenure.
• The document notes that it would be highly unusual for a former CEO to serve as a director of the same company so soon after departing as CEO.

Stakeholder Impact

• The outcome of the proxy vote will impact the composition of the Board of Directors and potentially influence the company's strategic direction.
• The company's performance and strategic decisions will affect stockholders, employees, and patients who rely on Zevra's therapies.
• The company's focus on rare disease therapies aims to improve the lives of patients with limited treatment options.

Next Steps

• Stockholders are urged to vote on the WHITE proxy card for the re-election of Wendy Dixon, Ph.D. and Tamara A. Favorito.
• The company will continue to focus on expanding the adoption of MIPLYFFA and OLPRUVA.
• Zevra will file a marketing authorization application (MAA) for MIPLYFFA in the EU in the second half of 2025.
• The company will accelerate enrollment in the Phase 3 DiSCOVER trial for celiprolol.

Key Dates

Keywords

proxy statement, board of directors, stockholder value, rare disease, Zevra Therapeutics, proxy fight, MIPLYFFA, OLPRUVA, celiprolol, Daniel J. Mangless